Radioimmunotherapy of lymphoma: A UC Davis experience

J. P. Lewis, Gerald L Denardo, S. J. Denardo

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

B-cell malignancies, such as malignant lymphoma and chronic lymphocytic leukemia, commonly present with advanced disease and multiple sites of involvement. Consequently, systemic combination chemotherapy is the standard therapeutic approach and cures about one half of these patients. Development of novel therapies is required if the remaining patients are to be cured of their malignancy. Lym-1, a mouse monoclonal antibody that is reactive with these malignancies, has been coupled with 131I or 67Cu and used to treat 55 patients with advanced B-cell malignancies that had proven resistant to standard therapy. The majority of the patients responded to this therapy and the survival of responders was longer than that of non-responders. Similar results have recently been reported by others. These results represent a remarkable achievement for single agent therapy because these trials were exploratory in nature and most of the patients had failed many chemotherapy regimens. The toxicities were in general mild and readily manageable. It appears that enhancing strategies are likely to improve upon these results by increasing the therapeutic index.

Original languageEnglish (US)
Pages (from-to)115-120
Number of pages6
JournalHybridoma
Volume14
Issue number2
StatePublished - 1995

Fingerprint

Radioimmunotherapy
Lymphoma
Neoplasms
B-Lymphocytes
Therapeutics
B-Cell Chronic Lymphocytic Leukemia
Combination Drug Therapy
Monoclonal Antibodies
Drug Therapy
Survival

ASJC Scopus subject areas

  • Genetics
  • Immunology

Cite this

Lewis, J. P., Denardo, G. L., & Denardo, S. J. (1995). Radioimmunotherapy of lymphoma: A UC Davis experience. Hybridoma, 14(2), 115-120.

Radioimmunotherapy of lymphoma : A UC Davis experience. / Lewis, J. P.; Denardo, Gerald L; Denardo, S. J.

In: Hybridoma, Vol. 14, No. 2, 1995, p. 115-120.

Research output: Contribution to journalArticle

Lewis, JP, Denardo, GL & Denardo, SJ 1995, 'Radioimmunotherapy of lymphoma: A UC Davis experience', Hybridoma, vol. 14, no. 2, pp. 115-120.
Lewis, J. P. ; Denardo, Gerald L ; Denardo, S. J. / Radioimmunotherapy of lymphoma : A UC Davis experience. In: Hybridoma. 1995 ; Vol. 14, No. 2. pp. 115-120.
@article{249456da93a14c02aa228372a70155fa,
title = "Radioimmunotherapy of lymphoma: A UC Davis experience",
abstract = "B-cell malignancies, such as malignant lymphoma and chronic lymphocytic leukemia, commonly present with advanced disease and multiple sites of involvement. Consequently, systemic combination chemotherapy is the standard therapeutic approach and cures about one half of these patients. Development of novel therapies is required if the remaining patients are to be cured of their malignancy. Lym-1, a mouse monoclonal antibody that is reactive with these malignancies, has been coupled with 131I or 67Cu and used to treat 55 patients with advanced B-cell malignancies that had proven resistant to standard therapy. The majority of the patients responded to this therapy and the survival of responders was longer than that of non-responders. Similar results have recently been reported by others. These results represent a remarkable achievement for single agent therapy because these trials were exploratory in nature and most of the patients had failed many chemotherapy regimens. The toxicities were in general mild and readily manageable. It appears that enhancing strategies are likely to improve upon these results by increasing the therapeutic index.",
author = "Lewis, {J. P.} and Denardo, {Gerald L} and Denardo, {S. J.}",
year = "1995",
language = "English (US)",
volume = "14",
pages = "115--120",
journal = "Monoclonal Antibodies in Immunodiagnosis and Immunotherapy",
issn = "2167-9436",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Radioimmunotherapy of lymphoma

T2 - A UC Davis experience

AU - Lewis, J. P.

AU - Denardo, Gerald L

AU - Denardo, S. J.

PY - 1995

Y1 - 1995

N2 - B-cell malignancies, such as malignant lymphoma and chronic lymphocytic leukemia, commonly present with advanced disease and multiple sites of involvement. Consequently, systemic combination chemotherapy is the standard therapeutic approach and cures about one half of these patients. Development of novel therapies is required if the remaining patients are to be cured of their malignancy. Lym-1, a mouse monoclonal antibody that is reactive with these malignancies, has been coupled with 131I or 67Cu and used to treat 55 patients with advanced B-cell malignancies that had proven resistant to standard therapy. The majority of the patients responded to this therapy and the survival of responders was longer than that of non-responders. Similar results have recently been reported by others. These results represent a remarkable achievement for single agent therapy because these trials were exploratory in nature and most of the patients had failed many chemotherapy regimens. The toxicities were in general mild and readily manageable. It appears that enhancing strategies are likely to improve upon these results by increasing the therapeutic index.

AB - B-cell malignancies, such as malignant lymphoma and chronic lymphocytic leukemia, commonly present with advanced disease and multiple sites of involvement. Consequently, systemic combination chemotherapy is the standard therapeutic approach and cures about one half of these patients. Development of novel therapies is required if the remaining patients are to be cured of their malignancy. Lym-1, a mouse monoclonal antibody that is reactive with these malignancies, has been coupled with 131I or 67Cu and used to treat 55 patients with advanced B-cell malignancies that had proven resistant to standard therapy. The majority of the patients responded to this therapy and the survival of responders was longer than that of non-responders. Similar results have recently been reported by others. These results represent a remarkable achievement for single agent therapy because these trials were exploratory in nature and most of the patients had failed many chemotherapy regimens. The toxicities were in general mild and readily manageable. It appears that enhancing strategies are likely to improve upon these results by increasing the therapeutic index.

UR - http://www.scopus.com/inward/record.url?scp=0029038357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029038357&partnerID=8YFLogxK

M3 - Article

C2 - 7590765

AN - SCOPUS:0029038357

VL - 14

SP - 115

EP - 120

JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

SN - 2167-9436

IS - 2

ER -